Speech and language deterioration in benign rolandic epilepsy.
A 5-year-old boy presented with typical clinical and electrophysiologic features of benign rolandic epilepsy. His neurodevelopment, language, and behavior prior to the onset of epilepsy were appropriately normal. He demonstrated marked deterioration of language and cognitive function during the course to a mild and then a moderate disability range. Serial sleep electroencephalographic recordings initially showed continuous and bilateral rolandic discharges with evolution to localized left rolandic spikes. Language and cognitive improvements were subsequently seen. Educational support and evolution of the electroencephalogram to a localized focus could have been contributory. It is anticipated, however, that he will have significant long-term problems in complex language.
Berroya
Anna G
AG
Department of Neurology, Sydney Children's Hospital, Randwick, New South Wales, Australia.
McIntyre
Jenny
J
Webster
Richard
R
Lah
Suncica
S
Sabaz
Mark
M
Lawson
John
J
Bleasel
Andrew F
AF
Bye
Ann M E
AM
D000849:Anomia / Q000175:diagnosis / Q000188:drug therapy; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004401:Dysarthria / Q000175:diagnosis* / Q000188:drug therapy; D004569:Electroencephalography / Q000187:drug effects; D019305:Epilepsy, Rolandic / Q000175:diagnosis* / Q000188:drug therapy; D005013:Ethosuximide / Q000009:adverse effects / Q000627:therapeutic use; D005071:Evoked Potentials / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007805:Language Development Disorders / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D009483:Neuropsychological Tests; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D013067:Speech Perception / Q000187:drug effects; D016896:Treatment Outcome; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D014706:Verbal Learning / Q000187:drug effects
D000927:Anticonvulsants; D002220:Carbamazepine; D005013:Ethosuximide; D014635:Valproic Acid; D011241:Prednisone